Voyager Therapeutics, INC

Voyager Therapeutics announced positive GLP toxicology data for its Alzheimer's gene therapy candidate, VY1706, demonstrating a favorable tolerability profile and effective CNS delivery in non-human primates.

Voyager Therapeutics announced an increase in authorized shares following its 2026 Annual Meeting of Stockholders.

Voyager Therapeutics announced its investigational tau gene therapy, VY1706, has received FDA clearance for an Investigational New Drug application, paving the way for a clinical trial in early Alzheimer's disease.

Voyager Therapeutics announced first quarter 2026 financial results, highlighting pipeline progress with IND-enabling studies completed for VY1706 and NBIB-233, and a cash runway extending into 2028.

Voyager Therapeutics announced the resignation of its Chief Financial Officer, Nathan Jorgensen, effective May 8, 2026, and the appointment of Robin Swartz as principal financial officer and treasurer.

Voyager Therapeutics announced the resignation of its Chief Medical Officer, Toby Ferguson, effective February 20, 2026, with CEO Alfred W. Sandrock, Jr. assuming interim responsibilities.

Voyager Therapeutics reports Q1 2026 results with reduced operating expenses and a strategic focus on key pipeline programs, while cash runway extends into 2028.

Voyager Therapeutics reported a significant increase in net loss and a sharp decline in collaboration revenue for Q3 2025, alongside a partial termination of key programs by Novartis.

Voyager Therapeutics reports a significant increase in net loss for Q2 2025, driven by strategic restructuring and R&D investments, while extending cash runway into 2028.

Voyager Therapeutics reports a net loss of $31.0 million for Q1 2025 while progressing its gene therapy and antibody programs targeting neurological diseases.

Voyager Therapeutics reported its Q3 2024 financial results, highlighting progress in its pipeline programs and strategic collaborations with Neurocrine and Novartis.

Voyager Therapeutics reported its second quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.

Voyager Therapeutics' 2024 10-K filing highlights progress in its gene therapy pipeline for neurological diseases, including Alzheimer's and Parkinson's, with key collaborations and upcoming clinical milestones.

Voyager Therapeutics and Novartis have entered into a licensing and collaboration agreement focused on developing gene therapies for spinal muscular atrophy and Huntingtons disease.

Voyager Therapeutics reports the grant of stock options to Director George A. Scangos under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics reports that Director Steven Hyman was granted 30,000 stock options under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics reports the grant of stock options to Director Nancy Vitale under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. reports a stock option grant to Director Michael J. Higgins, exercisable at $3.43 with a 10-year expiration.

Voyager Therapeutics reports a Form 4 filing detailing the grant of stock options to Director Jude Onyia.

Voyager Therapeutics, Inc. reports that Director James A. Geraghty was granted stock options under the company's 2025 Stock Incentive Plan.

Voyager Therapeutics announces its 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026, and proposes a significant increase in authorized common stock.

Voyager Therapeutics has scheduled its 2025 Annual Meeting for June 3, 2025, outlining proposals for stockholders to vote on, including the election of directors, executive compensation, and approval of stock incentive plans.

Voyager Therapeutics announces its 2025 Annual Meeting of Stockholders to be held on June 3, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and stock incentive plan approvals.

Voyager Therapeutics has scheduled its Annual Meeting for June 5, 2024, where stockholders will vote on director elections, executive compensation, and the ratification of the company's independent auditor.

Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young LLP as its independent auditor.

Several entities, including Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander, have jointly filed a Schedule 13G regarding their beneficial ownership of Voyager Therapeutics, Inc. common stock.

EcoR1 Capital, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed an amended Schedule 13G, reporting zero beneficial ownership in Voyager Therapeutics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5.87% of Voyager Therapeutics, Inc. common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Voyager Therapeutics Inc. following an internal realignment.

Millennium Management LLC and affiliated entities have reported a passive beneficial ownership of 6.1% in Voyager Therapeutics, Inc. common stock.

Armistice Capital, LLC and Steven Boyd reported a 7.57% beneficial ownership stake in Voyager Therapeutics, Inc. as of September 30, 2025.